CLL1 CAR T cells

CLL1 CAR T cells are an autologous chimeric antigen receptor (CAR) T-cell therapy designed to target C-type lectin-like molecule-1 (CLL1, also known as CLEC12A). CLL1 is a cell surface glycoprotein highly expressed on the blasts and leukemic stem cells (LSCs) of patients with acute myeloid leukemia (AML), while remaining absent on normal hematopoietic stem cells (HSCs). This expression profile makes CLL1 an attractive target for CAR-T therapy, as it potentially allows for the eradication of both bulk leukemia cells and the stem cell population responsible for relapse, with reduced risk of long-term myelosuppression. The therapy involves the genetic modification of a patient's own T cells to express a CAR that specifically recognizes CLL1, enabling these cells to selectively identify and kill CLL1-positive malignant cells. Clinical studies, such as those conducted by Guangdong Second Provincial General Hospital, are evaluating the safety and preliminary efficacy of these cells in patients with relapsed or refractory AML.

Other names

anti-CLL1 CAR-T cellsanti-CLL-1 CAR-T cellsanti-CLL 1 CAR-T cellsCLL-1 CAR-TCLL1 CAR-TCLL 1 CAR-TCLEC12A CAR-TCLEC-12A CAR-TCLEC 12A CAR-Tautogenous CLL1 CAR T cells